Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Biological: ALPP CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-08-15

Last Posted Date: 2024-10-23

Lead Sponsor: Xinqiao Hospital of Chongqing

Target Recruit Count: 9

Registration Number: NCT06556108

Locations: 🇨🇳
Department of Hematology, Xinqiao Hospital, ChongQing, Chongqing, China

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Phase 2

Recruiting

Conditions: Refractory Non-Hodgkin Lymphoma
Follicular Lymphoma
Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma
Relapsed Non-Hodgkin Lymphoma
Primary Mediastinal Large B-cell Lymphoma
High-grade B-cell Lymphoma

Interventions: Drug: Emapalumab
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Drug: Axicabtagene Ciloleucel

First Posted Date: 2024-08-12

Last Posted Date: 2024-12-19

Lead Sponsor: Marcela V. Maus, M.D.,Ph.D.

Target Recruit Count: 28

Registration Number: NCT06550141

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer

Phase 1

Recruiting

Conditions: Lung Cancer, Non-small Cell
Lung Cancer Recurrent
Lung Cancer
Lung Cancer Metastatic

Interventions: Biological: Tumor Infiltrating Lymphocytes (TIL)
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2
Drug: Pembrolizumab

First Posted Date: 2024-08-05

Last Posted Date: 2024-10-15

Lead Sponsor: Essen Biotech

Target Recruit Count: 85

Registration Number: NCT06538012

Locations: 🇨🇳
District One Hospital, Beijing, Beijing, China

Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies

Early Phase 1

Recruiting

Conditions: B-Cell Malignancy

Interventions: Genetic: Anti-CD19-CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-08-01

Last Posted Date: 2024-08-01

Lead Sponsor: Shanghai First Song Biotechnology Co., LTD

Target Recruit Count: 9

Registration Number: NCT06532630

Locations: 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects With Relapsed/Refractory Lymphoma

Early Phase 1

Recruiting

Conditions: Relapsed/Refractory Lymphoma

Interventions: Genetic: anti-CD20/CD30-CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-08-01

Last Posted Date: 2024-08-01

Lead Sponsor: Shanghai First Song Biotechnology Co., LTD

Target Recruit Count: 9

Registration Number: NCT06532643

Locations: 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

Phase 1

Recruiting

Conditions: Stomach Cancer
Stomach Cancer Recurrent
Stomach Cancer, Adenocarcinoma
Esophageal Cancer
Esophageal Cancer Metastatic to Bone
Esophageal Cancer Metastatic to Lung
Esophageal Cancer Metastatic to Liver

Interventions: Biological: Tumor Infiltrating Lymphocytes (TIL)
Drug: Cyclophosphamid
Drug: Fludarabine
Drug: Interleukin-2
Drug: Pembrolizumab

First Posted Date: 2024-08-01

Last Posted Date: 2024-11-12

Lead Sponsor: Essen Biotech

Target Recruit Count: 75

Registration Number: NCT06532799

Locations: 🇨🇳
District One Hospital, Beijing, Beijing, China

TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

Phase 1

Recruiting

Conditions: Breast Cancer
Breast Carcinoma
Breast Cancer Triple Negative
Breast Cancer Metastatic

Interventions: Biological: Tumor Infiltrating Lymphocytes (TIL)
Drug: Cyclophosphamid
Drug: Fludarabine
Drug: Interleukin-2
Drug: Pembrolizumab

First Posted Date: 2024-08-01

Last Posted Date: 2024-11-12

Lead Sponsor: Essen Biotech

Target Recruit Count: 85

Registration Number: NCT06532812

Locations: 🇨🇳
District One Hospital, Beijing, Beijing, China

Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer

Phase 1

Recruiting

Conditions: Colorectal Cancer
Colon Cancer
Rectum Cancer

Interventions: Biological: Tumor Infiltrating Lymphocytes (TIL)
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2
Drug: Pembrolizumab

First Posted Date: 2024-07-31

Last Posted Date: 2024-11-05

Lead Sponsor: Essen Biotech

Target Recruit Count: 85

Registration Number: NCT06530303

Locations: 🇨🇳
District One Hospital, Beijing, Beijing, China

Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma

Phase 1

Not yet recruiting

Conditions: HPV-Related Squamous Cell Carcinoma
HPV-Related Cervical Squamous Cell Carcinoma
HPV-Related Vulvar Squamous Cell Carcinoma
HPV-Related Penile Squamous Cell Carcinoma
HPV-Related Vaginal Squamous Cell Carcinoma
HPV-Related Anal Squamous Cell Carcinoma
HPV-Related Head and Neck Cancer

Interventions: Biological: SCG142
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-07-17

Last Posted Date: 2024-07-17

Lead Sponsor: SCG Cell Therapy Pte. Ltd.

Target Recruit Count: 66

Registration Number: NCT06505551

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Phase 2

Recruiting

Conditions: Large B-cell Lymphoma

Interventions: Device: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
Genetic: cemacabtagene ansegedleucel
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-07-15

Last Posted Date: 2024-11-29

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 250

Registration Number: NCT06500273

Locations: 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
University of Louisville Health Brown Cancer Center, Louisville, Kentucky, United States

and more 25 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy